Literature DB >> 6276143

Dopaminergic inhibition of pituitary beta-endorphin-like immunoreactivity secretion in the rat.

J M Farah, D S Malcolm, G P Mueller.   

Abstract

A pharmacologic approach was used to examine the possible role of dopamine neurons in the regulation of pituitary beta-endorphin-like immunoreactivity (beta-END-LI) secretion in the rat. Blockade of dopamine receptors by haloperidol or pimozide treatment evoked dose- and time-related increases in plasma levels of beta-END-LI. Physical immobilization increased circulating beta-END-LI six-fold and pretreatment with dopamine receptor agonists (bromocriptine or pergolide) significantly attenuated this rise without affecting plasma beta-END-LI levels in non-stressed animals. Dopaminergic drugs and immobilization produced similar effects on circulating PRL as on beta-END-LI. However, the magnitude of change in levels of PRL was generally greater than the change in beta-END-LI. The present findings suggest that dopaminergic neurons inhibit the release of pituitary beta-END-LI as well as PRL in the rat.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6276143     DOI: 10.1210/endo-110-2-657

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

Review 1.  Effects of catecholamines on secretion of adrenocorticotrophic hormone (ACTH) in man.

Authors:  S Al-Damluji; L H Rees
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

2.  Effects of bromocriptine on pituitary and adrenal cortex in pre-adrenarchal rabbits.

Authors:  R Pérez-Fernandez; F Facchinetti; T Garcia Caballero; A R Genazzani; J Devesa
Journal:  J Endocrinol Invest       Date:  1989-04       Impact factor: 4.256

3.  Regulation of the pro-opiomelanocortin mRNA levels in rat pituitary by dopaminergic compounds.

Authors:  C L Chen; F T Dionne; J L Roberts
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

Review 4.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

Review 5.  Roles of β-Endorphin in Stress, Behavior, Neuroinflammation, and Brain Energy Metabolism.

Authors:  Alexander Pilozzi; Caitlin Carro; Xudong Huang
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

Review 6.  Management and Medical Therapy of Mild Hypercortisolism.

Authors:  Vittoria Favero; Arianna Cremaschi; Alberto Falchetti; Agostino Gaudio; Luigi Gennari; Alfredo Scillitani; Fabio Vescini; Valentina Morelli; Carmen Aresta; Iacopo Chiodini
Journal:  Int J Mol Sci       Date:  2021-10-26       Impact factor: 5.923

Review 7.  Dopamine Agonists for Pituitary Adenomas.

Authors:  Odelia Cooper; Yona Greenman
Journal:  Front Endocrinol (Lausanne)       Date:  2018-08-21       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.